Abstract
The development of cancer immunotherapy has long been a challenge. Here, we report that prophylactic vaccination with a highly attenuated Trypanosoma cruzi strain expressing NY-ESO-1 (CL-14-NY-ESO-1) induces both effector memory and effector CD8(+) T lymphocytes that efficiently prevent tumor development. However, the therapeutic effect of such a vaccine is limited. We also demonstrate that blockade of Cytotoxic T Lymphocyte Antigen 4 (CTLA-4) during vaccination enhances the frequency of NY-ESO-1-specific effector CD8(+) T cells producing IFN-γ and promotes lymphocyte migration to the tumor infiltrate. As a result, therapy with CL-14-NY-ESO-1 together with anti-CTLA-4 is highly effective in controlling the development of an established melanoma.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antigens, Neoplasm / administration & dosage
-
Antigens, Neoplasm / genetics
-
Antigens, Neoplasm / immunology*
-
CD8-Positive T-Lymphocytes / immunology*
-
CD8-Positive T-Lymphocytes / parasitology
-
CTLA-4 Antigen / antagonists & inhibitors
-
CTLA-4 Antigen / immunology*
-
Cancer Vaccines / immunology*
-
Female
-
Humans
-
Immunotherapy / methods*
-
Melanoma, Experimental / immunology
-
Melanoma, Experimental / parasitology
-
Melanoma, Experimental / therapy*
-
Membrane Proteins / administration & dosage
-
Membrane Proteins / genetics
-
Membrane Proteins / immunology*
-
Mice
-
Mice, Inbred C57BL
-
Recombinant Proteins / administration & dosage
-
Recombinant Proteins / genetics
-
Recombinant Proteins / immunology
-
Trypanosoma cruzi / genetics
-
Trypanosoma cruzi / immunology
Substances
-
Antigens, Neoplasm
-
CTAG1B protein, human
-
CTLA-4 Antigen
-
CTLA4 protein, human
-
Cancer Vaccines
-
Membrane Proteins
-
Recombinant Proteins